1. Home
  2. CPAC vs URGN Comparison

CPAC vs URGN Comparison

Compare CPAC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cementos Pacasmayo S.A.A. (Each representing five)

CPAC

Cementos Pacasmayo S.A.A. (Each representing five)

HOLD

Current Price

$10.38

Market Cap

905.9M

Sector

Industrials

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$23.00

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPAC
URGN
Founded
1949
2004
Country
Peru
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
905.9M
1.1B
IPO Year
2012
2017

Fundamental Metrics

Financial Performance
Metric
CPAC
URGN
Price
$10.38
$23.00
Analyst Decision
Sell
Strong Buy
Analyst Count
2
8
Target Price
$10.15
$28.50
AVG Volume (30 Days)
203.3K
773.4K
Earning Date
02-13-2026
11-06-2025
Dividend Yield
5.31%
N/A
EPS Growth
20.27
N/A
EPS
0.15
N/A
Revenue
$601,081,883.00
$96,516,000.00
Revenue This Year
$9.96
$27.96
Revenue Next Year
$1.70
$123.20
P/E Ratio
$13.74
N/A
Revenue Growth
6.18
8.00
52 Week Low
$5.10
$3.42
52 Week High
$11.30
$30.00

Technical Indicators

Market Signals
Indicator
CPAC
URGN
Relative Strength Index (RSI) 73.92 48.27
Support Level $10.27 $22.60
Resistance Level $10.69 $24.14
Average True Range (ATR) 0.55 1.17
MACD 0.24 -0.08
Stochastic Oscillator 80.36 46.53

Price Performance

Historical Comparison
CPAC
URGN

About CPAC Cementos Pacasmayo S.A.A. (Each representing five)

Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: